Panacea-ml
Ra'anana
About Panacea-ml
Panacea-ml revolutionizes clinical trial design with its data-driven, explainable-AI SaaS platform. Our cutting-edge technology addresses the primary causes of clinical development failure by identifying patient profiles that maximize therapeutic efficacy, minimize safety risks, and improve participant retention. Leveraging historical clinical trials and millions real-world patient health records, Panacea-ml's AI model enhances patient selection criteria, reduces cohort sizes, and uncovers novel marker-endpoint interrelations, surrogate markers, and causal relationships beyond simple statistical correlations. Our platform is a game-changer for the pharmaceutical industry, facilitating seamless collaboration across drug development, data science, and clinical teams. It accelerates drug development by generating precise sub-population profiles, refining patient selection criteria, and providing informed go/no-go decisions for each phase of development. Panacea-ml is versatile, supporting small sample sizes and various therapeutic domains, including rare diseases and early development stages. At Panacea-ml, we believe in empowering innovation and fostering collaboration to drive impactful outcomes. Our mission is to shorten time to market and enable early access to innovative treatments for patients worldwide.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.0M
- Funding stage: Seed
- Last round: Non-Equity Assistance (Jul 2024)
- Website: panacea-ml.com
- Phone: +972-58-6906556
Industries & Categories
Analytics, Artificial Intelligence (AI), Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/panacea-ml-28850 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.